These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26124203)

  • 1. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
    Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
    Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siltuximab for multicentric Castleman disease.
    Liu YC; Stone K; van Rhee F
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
    Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
    Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA
    BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose selection of siltuximab for multicentric Castleman's disease.
    Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
    Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Kurzrock R
    Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
    Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 as a therapeutic target.
    Rossi JF; Lu ZY; Jourdan M; Klein B
    Clin Cancer Res; 2015 Mar; 21(6):1248-57. PubMed ID: 25589616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
    Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
    Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
    Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
    Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
    Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N
    Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
    Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H
    Clin Cancer Res; 2019 Jul; 25(13):3772-3775. PubMed ID: 30890552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
    Med Lett Drugs Ther; 2015 Jan; 57(1459):e8. PubMed ID: 25555075
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
    Isaacs JD; Harari O; Kobold U; Lee JS; Bernasconi C
    Arthritis Res Ther; 2013; 15(6):R204. PubMed ID: 24295403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.